| Cash Flow | 2025-06-30 |
|---|---|
| Net Income Loss | -10,523,246 |
| Net loss | -10,523,246 |
| Stock-based compensation | 488,274 |
| Amortization of right-to-use operating lease asset | 391,417 |
| Prepaid expenses and other current assets | 169,143 |
| Operating lease liability | -422,881 |
| Accrued liabilities | -404,289 |
| Accounts payable | 561,901 |
| Depreciation expense | 145,715 |
| Stock-based inducement expense | 863,550 |
| Net cash used in operating activities | -9,068,702 |
| Payments for short term borrowings | 0 |
| Payment of sponsor loans | 0 |
| Proceeds from exercise of pre-funded warrants | 203 |
| Proceeds from short-term borrowings, net | 0 |
| Proceeds from share purchases under eloc, net of issuance costs | 2,425,906 |
| Proceeds received from sale of pre-funded warrants, net of issuance costs | 3,685,027 |
| Proceeds from issuance of series a preferred stock, net of issuance costs | 0 |
| Proceeds received from sale of common stock and warrants | 588,000 |
| Cash redemption of series c preferred stock | 395,000 |
| Proceeds received from sale of series d preferred stock, net of issuance costs | 2,240,180 |
| Proceeds received from sale of series b preferred stock | 0 |
| Proceeds from exercise of series a preferred warrants | 500,000 |
| Advances from shareholder | 0 |
| Net cash provided by financing activities | 9,044,316 |
| Net increase (decrease) in cash and cash equivalents | -24,386 |
CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERO THERAPEUTICS HOLDINGS, INC. (CERO)